Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Rawat, Swati
- An Analytical Approach of Doxofylline:A Review
Abstract Views :465 |
PDF Views:0
Authors
Affiliations
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
Source
Asian Journal of Pharmaceutical Analysis, Vol 1, No 4 (2011), Pagination: 67-70Abstract
Doxofylline is chemically designated as 7-(1, 3 dioxolone-2-yl methyl) theophylline. Presence of a dioxolane group in position C-7 differentiates it from theophylline. It is a new antibronchospastic drug recently introduced in therapy with pharmacological properties like theophylline; a potent adenosine receptor antagonist. doxofylline do not affect gastric acid secretion; either invivo or in-vitro; unlike theophylline. The lack of side effects with doxofylline indicates that the drug can be used safely and effectively. Some analytical methods for quantitative determination of doxofylline in pharmaceutical formulations like UV-Spectrophotometry, HPLC and LC-MS are reported. The present review deals with the various analytical methods reported as well as adopted for the estimation of doxofylline.Keywords
Doxofylline, UV, HPLC, LC-MS.- Method Development and Photolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS
Abstract Views :277 |
PDF Views:0
Authors
Affiliations
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 Alkem Laboratories, Mumbai, IN
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 Alkem Laboratories, Mumbai, IN
Source
Asian Journal of Pharmaceutical Analysis, Vol 1, No 2 (2011), Pagination: 29-33Abstract
A simple, rapid and accurate RP-HPLC method was developed for the determination of doxofylline and photolytic degradation product. The method showed a linear response for concentrations in the range of 1-200 g/ml using acetonitrile: formic acid (90: 10); pH-3.0 as the mobile phase with detection at 274 nm and a flow rate of 1 ml/min and retention time 2.9 min. The method was statistically validated for accuracy, precision, linearity, ruggedness, robustness, forced degradation, solution stability and selectivity. Quantitative and recovery studies of the dosage form were also carried out and analyzed; the % RSD from recovery studies was found to be less than 1. Due to simplicity, rapidity and accuracy of the method, we believe that the method will be useful for routine quality control analysis. The acid degradation product as well as pathway was characterized by LC-MS/MS.Keywords
Doxofylline, RP-HPLC, LC-MS/MS, Degradation Studies.- Method Development and Acid Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS
Abstract Views :242 |
PDF Views:0
Authors
Affiliations
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 IIT, Mumbai (M.S.), IN
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 IIT, Mumbai (M.S.), IN
Source
Asian Journal of Pharmaceutical Analysis, Vol 1, No 1 (2011), Pagination: 10-13Abstract
A simple, rapid and accurate RP-HPLC method was developed for the determination of doxofylline and acid degradation product. The method showed a linear response for concentrations in the range of 1-200 μg/ml using acetonitrile: formic Acid (90: 10); pH-3.0 as the mobile phase with detection at 274 nm and a flow rate of 1 ml/min and retention time 2.9 min. The method was statistically validated for accuracy, precision, linearity, ruggedness, robustness, forced degradation, solution stability and selectivity. Quantitative and recovery studies of the dosage form were also carried out and analyzed; the % RSD from recovery studies was found to be less than 1. Due to simplicity, rapidity and accuracy of the method, we believe that the method will be useful for routine quality control analysis. The acid degradation product as well as pathway was characterized by LC-MS/MS.Keywords
Doxofylline, RP-HPLC, LC-MS/MS, Degradation Studies.- Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS
Abstract Views :247 |
PDF Views:0
Authors
Affiliations
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 IIT Mumbai (M.S), IN
1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
3 IIT Mumbai (M.S), IN
Source
Asian Journal of Pharmaceutical Analysis, Vol 1, No 1 (2011), Pagination: 14-18Abstract
A simple, rapid and accurate RP-HPLC method was developed for the determination of doxofylline and photolytic degradation product. The method showed a linear response for concentrations in the range of 1-200 μg/ml using acetonitrile: formic acid (90:10); pH-3.0 as the mobile phase with detection at 274 nm and a flow rate of 1 ml/min and retention time 2.9 min. The method was statistically validated for accuracy, precision, linearity, ruggedness, robustness, forced degradation, solution stability and selectivity. Quantitative and recovery studies of the dosage form were also carried out and analyzed; the % RSD from recovery studies was found to be less than 1. Due to simplicity, rapidity and accuracy of the method, we believe that the method will be useful for routine quality control analysis. The hydrolytic degradation product as well as pathway was characterized by LC-MS/MS.Keywords
Doxofylline, RP-HPLC, LC-MS/MS, Degradation Studies.- Development and Study of Wound Healing Activity of an Ayurvedic Formulation
Abstract Views :233 |
PDF Views:0
Authors
Affiliations
1 Shri Bhagwan College of Pharmacy Aurangabad (M.S.), IN
2 Kunwar Haribansh Singh College of Pharmacy Jaunpur (U.P.), IN
1 Shri Bhagwan College of Pharmacy Aurangabad (M.S.), IN
2 Kunwar Haribansh Singh College of Pharmacy Jaunpur (U.P.), IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 1, No 1 (2011), Pagination: 26-28Abstract
The effect of prepared Ayurvedic formulation was evaluated on excision and incision wound models in rats. The wound-healing activity was assessed by the rate of period of epithelialization and skin-breaking strength. Histological study of the granulation tissue was carried out to know the extent of collagen formation in the wound tissue. The Ayurvedic formulation prepared was then promoted for wound-healing activity in two wound models. The treated animals showed significant reduction in the wound area up to (P<0.001) and faster rate of epithialisation (23.17±0.54). In an incision wound model, formulation treated animals demonstrated significant skin-breaking strength up to 420.33±5.92. Histological studies of the tissue obtained from the formulation treated group revealed that the activity was more significant in this group. Our present study reveals that the Ayurvedic formulation posses potent wound healing activity, which could be a good choice of remedy for wound healing but less potent than standard Nitrofurazone.Keywords
Excision Wound, Incision Wound Model, Ayurvedic Medicinal Plants.- Regulatory Requirements for Drug Development and Approval in United States:A Review
Abstract Views :214 |
PDF Views:1
Authors
Affiliations
1 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
2 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
1 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.), IN
2 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.), IN
Source
Asian Journal of Pharmaceutical Research, Vol 1, No 1 (2011), Pagination: 1-6Abstract
In this paper a brief history and an overview of the regulatory process for drug approval in the United States through illustrations of Investigational New Drug (INDs) Applications and New Drug Applications (NDAs), abbreviated new drug applications (ANDAs) and supplemental new drug applications (SNDAs) are provided. For INDs, the regulatory requirements for a well-designed protocol, the role and responsibility of institutional review boards, and the applicability of treatment INDs are discussed. For NDAs, issues regarding the application of expanded access, the submission of abbreviated NDAs for a generic drug, the submission of supplemental NDAs for labeling changes, and the role and responsibility of advisory committees are addressed. Along with this a brief description of review steps taken by FDA is provided.Keywords
Investigational New Drug Application, New Drug Application, International Conference on Harmonization.- Clinical Importance of Aloe Vera:Review
Abstract Views :596 |
PDF Views:0
Authors
Affiliations
1 Surgycare Lifescience, Sendhwa (MP), IN
2 SND College of Pharmacy, Yeola (MS), IN
1 Surgycare Lifescience, Sendhwa (MP), IN
2 SND College of Pharmacy, Yeola (MS), IN
Source
Research Journal of Topical and Cosmetic Sciences, Vol 8, No 1 (2017), Pagination: 30-39Abstract
John Goodyew translated first reference from term ‘Dioscorides Medical treatise De Materia Medica’ into English terminology as use of Aloe vera in A.D. 1655; moreover, in early 1800s it used as laxative whereas in the mid 1930s successful treatment was introduced for chronic and severe radiation dermatitis. Since, several cultures of the history have been showed impression of foot print for use of Aloe vera, major includes Greece, Egypt, India, Mexico, Japan and China. Egyptian queens Nefertiti and Cleopatra regularly involved it in their beauty regimes whereas Alexander the Great, and Christopher Columbus used it to treat soldiers’ wounds. Aloe vera is well known plant not only in tribal community but modern lookout also make it therapeutic important. Since it is used in Ayurvedic, Homeopathic and Allopathic medicine because various research support that it contains vitamins, minerals, enzymes, amino acids, natural sugar and other bioactive compounds. Although therapeutic use of Aloe vera covered wide range of activity major includes emollient, purgative, antimicrobial, anti inflammatory, antioxidant, aphrodisiac, anti-helmenthic, antifungal, antiseptic and cosmetic, its benefits so myriad and astounding that no part in human body remains uninfluenced by its healing touch; all these make it plant of wonder. The modern therapeutic approach for beauty enhancer also list Aloe vera as most favorable plant in cosmetic industries. In this review we are trying to approach and underlying every possible corner associated with medicinal use of Aloe vera.Keywords
Aloe vera, Wound Healing Agent, Antioxidant, Laxative, Anticancer, Anti Stress, Antidiabetic, Antidiabetic, Nutrient.References
- Davis, RH, Parker WL, Samson RT, and Murdoch DP. The isolation of an active inhibitory sytem from an extract of Aloe vera. J. Am Podiatr Med Assoc 81; 1991: 258-261.
- Lopez, H, Camberros LO, and Ocampo AA. Comparative evaluation of a mixture of propolis and Aloe vera with commercial wound healing products. Veterinaria 20(4); 1989:407-414.
- Tyler V. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies, Third Edition. Pharmaceutical Products Press, Binghamton, NY. 1993.
- Grindlay D, Reynolds T. The Aloe vera phenomenon: a review of the properties and modern uses of the leaf parenchyma gel. J ethnopharmacology. 16(1); 1986:117–15.
- Foster S, et al. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. Haworth Herbal Press, New York. 1999.
- Davis RH. Aloe vera: A scientific approach. Vantage Press, New York. 2000.
- Brusick D, Mengs U. Assessment of the genotoxic risk from laxative senna products. Environmental and Molecular Mutagenesis 29(1); 1999:1-9.
- Okamura N, Asai M, Hine H, and Yagi A. J. Chromatography.746(1); 1996: 225-233.
- Jyotsana M, Sharma AK, Inamdar N, Harwinder Singh R and Ramnik S. Immunomodulatory properties of Aloe veragel in mice. Int J Green Pharmacy. 2(1);2008: 152-154.
- Davis RH, Leitner MG, Russo JM and Byrne ME. Wound healing. Oral and topical activity of Aloe vera. J American Paediatric Medical Association. 79(1); 1989: 559-562.
- Satish S, Raveesha KA and Janardhana GR. Antibacterial activity of plant extracts on phytopathogenic Xanthomonas campestris pathovars. Letters in Applied Microbiology 28; 1999; 145-147.
- Zhang L and Tizard IR. Activation of mouse macrophage cell line by Acemannan; the major carbohydrate fraction of Aloe vera L. Immunopharmacology 35; 1996: 119-28.
- Vogler BK and Ernst E. Aloe vera: A systematic review of its clinical effectiveness. The British journal of general practice: J Royal College of General Practitioners 49; 1999:823-828.
- King GK, Yates KM and Greenlee PG. The effect of acemannan immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. J American Animal Hospital Association 31; 1995: 439 -447.
- Dagne E, Bisrat D, Viljoen A and Van Wyk BE. Chemistry of Aloe species. J Current Organic Chemistry 4; 2000: 1055-1078.,
- Ombrello T. Aloe vera . http://faculty.ucc.edu/biology - ombrello /POW /Aloe_ vera. htm 2008, Accessed 2008/06/08.
- Nassiff HA and Fajardo F, Velez F. Effect of aloe AS hiperlipidemia. Rev Cuba Med Gen Integr.9; 1993: 43-51.
- Reddy Uma CH, Reddy SK and Reddy J. Aloe vera - A wound healer. Asian Journal of Oral Health and Allied Sciences 1; 2011: 91 -92.
- Shamim S, Ahmed S, Waseemuddin and Azhar I. Anti fungal activity of Allium, Aloe, and Solanum species. Pharmaceutical Biology 42; 2004:491-498.
- Ferro VA, Bradbury F, Cameron P, Shakir E, Rahman SR and Stimson WH. In vitro susceptibilities of Shigella flexneri and Streptococcus pyogenes to inner gel of Aloe barbadensis Miller. Antimicrobial agents and chemotherapy 47; 2003: 1137-1139.
- D Jasso de Rodriguez, Hernandez Castillo D, Rodriguez Garcia R and Angulo-Sanchez J L. Antifungal activity in vitro of Aloe vera pulp and liquid fraction against plant pathogenic fungi. Industrial Crops and Products. 21; 2005: 81-87.
- Hashemi SA, Madani SA, Saied A. The Review on Properties of Aloe Vera in Healing of Cutaneous Wounds. BioMed Research International. 2015(1); 2015:1-7
- Heggie S, et al. A Phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs. 25(6); 2002:442-51.
- Williams M, et al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys. 36(2); 1996:345-349.
- Ganapathy N, Venkataraman SS, Daniel R. Molecular biology of wound healing. Journal of Pharmacy and Bioallied Sciences, vol. 4(6); 2012, 334-337.
- Chithra P, Sajithlal GB, Chandrakasan G. Influence of Aloe vera on collagen characteristics in healing dermal wounds in rats. Mol Cell Biochem. 181; 1998:71-76.
- Fulton JE Jr. The stimulation of postdermabrasion wound healing with stabilized aloe vera gel-polyethylene oxide dressing. J Dermatol Surg Oncol. 16; 1990:460-467.
- Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant extracts on skin and skin disorders. Adverse Drug React Toxicol Rev. 20(2); 2001:89-103.
- Davis RH, Leitner MG, Russo JM, Byrne ME. Wound healing. Oral and topical activity of aloe vera. Journal of the American Podiatric Medical Association 79; 1989:559-562.
- Newton LE . In defence of the name Aloe vera. The cactus and succulent journal of Great Britain. 41; 1979:29-30.
- Heggers JP, Pelley RP, Robson MC. Beneficial effects of Aloe in wound healing. Phytotherapy research. 7; 1993:S48–S52.
- Shelton RM. Aloe vera, its chemical and therapeutic properties. International journal of dermatology. 30; 1991:679-683.
- Davis, RH, et al. Anti-inflammatory and wound healing activity of a growth substance in Aloe vera. Journal of the American Podiatric Medical Association. 84(2); 1994: 77-81.
- Tizard AU et al. Effects of acemannan, a complex carbohydrate, on wound healing in young and aged rats. Wounds, a compendium of clinical research and practice 6; 1995:201-209.
- Roberts DB, Travis EL. Acemannan-containing wound dressing gels reduce radiation-induced skin reactions in C3H mice. International journal of radiation oncology, biology and physiology 15; 1995:1047-1052.
- Saroj PL, D handar DG and Singh RS. Indian Aloe. Central Institute for Arid Horticulture, Bikaner 2004: 6-10.
- Mortan JF. Folk uses and commercial exploitation of Aloe veraleaf pulp. Economic Botany15; 1961:311-319.
- Femenia A, Sanchez ES, Simal S and Rosello C. Compositional features of polysaccharides from Aloe vera (Aloe barbadensis Miller) plant tissues.arbohydr. Polym.39; 1999: 109-117.
- Sims P, Ruth M and Zimmerman ER. Effect of Aloe veraon Herpes simplex and herpes virus (strain Zoster). Aloe vera of Amer ican Archives 1;1971:239-240.
- Stone N, Meistar A. Function of ascorbic in the conversion of proline to collagen hydroxyproline. Nature 194;1965: 555-57.
- El-Shemy HA, Aboul-Soud MA, Nassr-Allah AA, Aboul-Enein KM, Kabash A and Yagi A. Antitumor properties and modulation of antioxidant enzymes' activity by Aloe vera leaf active principles isolated via supercritical carbon dioxide extraction. Current Organic Chemistry 17;2010: 129-138.
- Kirtikar KR and Basu BD. Indian Medicinal Plants. Vol. IV (IIndEd.).Pub. Lalit Mohan Basu, Allahabad, India, 1989.
- Davis HR. Aloe vera: A Scientific Approach Published by Vantage Press NewYork, SA. http://www.aloevera.co.uk/rhdavis.htm 1997, Accessed 2011/07/07.
- Barcroft SL and Alasdair NT. Aloe vera Healer, (www .JoJaffa.com), http://www.AloeVeraHealer.com, 1999, Accessed 2011/03/09.,
- Yates A. Yates Garden Guide. Harper Collins Australia 2002, pp.135-137.
- Jones K and Aloe C. The anti-diabetic activity of Aloe vera. Cosmetic Science Technology 2; 2005: 34-35
- Green P. Aloe vera extracts in equine clinical practice. Veterinary Times 26; 1996:9-12.'
- Gordon MC and David JN. Natural product drug discovery in the next millennium. Pharm. Biology39; 2001: 8-17.
- Mckeown E. Anthraquinones and anthracenic derivatives absorb UV light. Cosmetics and toiletries. 102; 1987:64-65.
- Leigh GC. Dental irrigators. Research letters Br. Dent. Journal 198; 2005: 756-763.
- Kaufman T, Kalderon N, Ullmann Y, et al. Aloe vera gel hindered wound healing of experimental second-degree burns: a quantitative controlled study.J Burn Care Rehabil. 9; 1988:156-159.
- Crowell J, Penneys N. The effects of aloe vera on cutaneous erythema and blood flow following ultraviolet B (UVB) exposure. Clin Res. 35; 1987:676A.
- Syed TA, Cheema KM, Ashfaq A, et al. Aloe vera extract 0.5% in ahydrophilic cream versus Aloe vera gel for the management of genital herpes in males. A placebo-controlled, double-blind, comparative study [letter]. J Eur Acad Dermatol Venereol. 7;1996: 294-295.
- Syed TA, Ahmad SA, Holt AH, et al. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Trop Med Int Health. 1; 1996:505-509.
- Vardy DA, Cohen AD, Tchetov T, et al. A double-blind, placebo-controlled trial of an Aloe vera (A. barbadensis) emulsion in the treatment of seborrheic dermatitis. J Dermatol Treat. 10; 1999:7-11.
- Udupa, SL, Udupa AL and Kulkarni DR. Anti-inflammatory and wound healing properties of Aloe vera. Fitoterapia. 65(2); 1994: 141-145.,
- Davis, RH et al. Aloe vera, hydrocortisone, and sterol influence on wound tensile strength and anti-inflammation. Journal of the American Podiatric Medical Association. 84(12); 1994: 614-21.
- Tucker AO, Duke JA, Foster S. Botanical nomenclature of medicinal plants. In: Cracker LE, Simon JE, eds. Herbs, spices and medicinal plants, Vol. 4. Phoenix, AR, Oryx Press, 1989:169–242.
- Robson MC, Heggers J, Hagstrom WJ. Aloe vera revisited. Journal of burn care and rehabilitation, 3; 1982:157-162.
- Udupa, SL, Udupa AL and Kulkarni DR. Anti-inflammatory and wound healing properties of Aloe vera. Fitoterapia 65(2); 1994: 141-145.
- Davis, RH, et al. Anti-inflammatory and wound healing activity of a growth substance in Aloe vera. Journal of the American Podiatric Medical Association. 84(2); 1994: 77-81.
- Lee KH, et al. Anti-leukaemic and anti-mutagenic effects of di(2-ethylhexyl)phthalate isolated from Aloe vera Linne. J Pharm Pharmacol. 52(5); 2000:593-8.
- Pulse, T. 1988. Whole leaf Aloe vera juice used in AIDS treatment. About Aloe vera. (obtained from defunct webpage).
- Atherton Peter. Aloe vera Myth or Medicine? Positive Health Publications, www.positivehealth.com/permit/Articles/AloeVera/atherton.htm, Online, 2002, Accessed 2011/05/13.
- Rodriguez DJ, Hernandez CD, Rodríguez GR and Angulo Sanchez JL. Antifungal activity in vitro of Aloe vera pulp and liquid fraction against plant pathogenic fungi. Industrial Crops and Products 21; 2005:81-87.
- Lee JK, et al. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int Immunopharmacol. 1(7); 2001:1275-84.
- Pugh N, et al. Characterization of Aloeride, a new high-molecular-weight polysaccharide from Aloe vera with potent immunostimulatory activity. J Agric Food Chem. 49(2); 2001:1030-4.
- Reynolds T, Aloes: The Genus Aloe, CRC press, 2004.
- Lee KH, et al. Anti-leukaemic and anti-mutagenic effects of di(2-ethylhexyl)phthalate isolated from Aloe vera Linne. J Pharm Pharmacol. 52(5); 2000:593-8.
- Zhang L, Tizard IR. Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Immunopharmacology. 35(2); 1996:119-28.
- Furukawa F, et al. Chemopreventive effects of Aloe arborescens on N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Cancer Lett. 25;178(2); 2002:117-22.
- Vogler BK and Ernst E. Aloe vera: A systematic review of its clinical effectiveness. The British journal of general practice: The journal of the Royal College of General Practitioners 49;1999, 823-828.
- Yeh GY, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 26(4); 2003: 1277-94.
- Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant extracts on skin and skin disorders. Adverse Drug React Toxicol Rev. 20(2); 2001: 89-103.
- Al Awadi F, Fatania H, Shamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats. Diabetes Research 18; 1991:163-168.
- Crowell J, Penneys N. The effects of aloe vera on cutaneous erythema and blood flow following ultraviolet B (UVB) exposure. Clin Res. 35; 1987:676-678.
- Chithra P, Sajithlal GB, Chandrakasan G. Influence of Aloe vera on collagen characteristics in healing dermal wounds in rats. Mol Cell Biochem. 181; 1998:71-76.
- Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract. 49(447); 1999:823-828.
- Ghannam N, Kingston M, Al Meshaal IA, Tariq M, Parman NS, Woodhouse N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. Horm Res. 24(4); 1986:288-94.
- Davis RH, Leitner MG, Russo JM and Byrne ME. Wound healing.Oral and topical activity of Aloe vera. Journal of the American Paediatric Medical Association 79; 1989: 559–562.
- Cheesbrough M. Medical Laboratory Manual for Tropical Countries. Vol. II, first edition. Printed and bond in Great Britain by the university Press, Cambridge 1984, pp. 372-391.
- Grindlay D and Reynadds T. The Aloe vera Phenomenon. A review of the properties and modern uses of the leaf parenchyma gel. J.Ethnopharmacol 16; 1986:117-151.
- Neall B. Aloe’s new role in functional foods. Food Review 31; 2004: 24-25.
- Anonymous. Water conservation. Chennai, India: The Hindu, India. 2008c, http://www.hindu.co/seta/2008/07/10/stories.2008071050161 800. htm . Accessed 2010/12/15.,
- Nadkerni KM. Indian Meteria Medica Vol. I (3rd ed.). Pub. Bommbay Popular Prakashan Private Limited. 1976, pp. 73-74.
- Joseph B and Justin Raj S. Pharmacognostic and phytochemical properties of Aloe vera Linn. - An overview. International Journal of Pharmaceutical Science Review and Research 2; 2010: 106-110.
- Thomson PDR. Herbal Medicines, Third Edition, NJ: Thomson PDR. 2004, Pp.16-20.
- Marshall J. Aloe vera gel: what is the evidence? Pharmaceutical Journal 244; 2000: 360-362.
- Agarry OO, Olaleye MT and Bello-Michael CO. Comparative antimicrobial activities of Aloe vera gel and leaf. African Journal of Biotechnology 4; 2005: 1413-1414.
- Langmead L, Makins RJ and Rampton DS. Anti-inflammatory effects of Aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 19;2004b: 521-527.
- Rabe T and Staden J Van. Antibacterial activity of South African plants used for medicinal purposes. Journal of Ethnopharmacology 56; 1997: 81-87.
- Davis RH, Leitner MG, Russo JM and Byrne ME. Wound healing. Oral and topical activity of Aloe vera. Journal of the American Paediatric Medical Association 79;1989: 559-562.
- Liao Z, Chen M, Tan F, Sunl X and Tang K. Microprogagation of endangered Chinese aloe Plant Cell, Tissue and Organ Culture 76;2004: 83-86.
- Zhang L and Tizard IR. Activation of mouse macrophage cell line by Acemannan; the major carbohydrate fraction of Aloe vera L. Immunopharmacology 35; 1996: 119-28.
- Nassiff HA and Fajardo F, Velez F. Effecto del aloe sobre la hiperlipidemia en pacientes refractarios a diet. Rev Cuba Med Gen Integr. 9;1993: 43-51.
- Barcroft S L and Alasdair N T. Aloe vera Healer,(www.JoJaffa.com), http://www. AloeVeraHealer.com, 1999,Accessed 11/03/09.86.
- Zhang L and Tizard IR. Activation of mouse macrophage cell line by Acemannan; the major carbohydrate fraction of Aloe vera L. Immunopharmacology 35; 1996: 119-28.
- Rolf C and Zimmerli T. Experience Aloe vera is miraculous health supporting benefits. http://wholeleaf.com 2000, Accessed 2011/08/17.
- Newall CA, Anderson LA and Phillipson JD. Herbal medicines. The pharmaceutical Press wilkensiana. Journal of Ethnopharmacology 25; 1996a: 215-220.
- Tyler VE, Brady LR and Robbers JE. Pharmacognosy. Philadelphia: Lea and Febiger 2; 1976: 81-83.]
- Anonymous. Taxon: Aloe vera (L) Burm. Germplasm Resources Information Network, United States Department of Agriculture 2008b, http://www.ars-grin.gov/cgibin/npgs/html/tax_search.pl?Aloe%20vera, Accessed 2011/08/27.
- Tyler V. Herbs of Choice: The Therapeutic Use of Phytomedicinals. Binghamton, NY: Pharmaceutical Products Press; 1994. , Brusick D, Mengs U. Assessment of the genotoxic risk from laxative senna products. Environmental and Molecular Mutagenesis 29; 1997:1-9.
- Foster S, et al. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. New York: Haworth Herbal Press; 1999.
- Borrelli F, Izzo AA. The plant kingdom as a source of anti-ulcer remedies. Phytother Res. 14(8); 2000:581-91.
- Langmead L, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 19(7); 2004:739-47.
- Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract. 49(447); 1999:823-8.
- Pharmacoepidemiology of Severe Systemic Infection and Need of Netilmicin Monotherapy or Combination Therapy:Systemic Review and Meta- Analysis
Abstract Views :229 |
PDF Views:0
Authors
Affiliations
1 Surgycare Lifescience, Sendhwa (MP), IN
2 SND College of Pharmacy, Yeola (MS), IN
3 RD Memorial Ayurvedic College, Bhopal (MP), IN
1 Surgycare Lifescience, Sendhwa (MP), IN
2 SND College of Pharmacy, Yeola (MS), IN
3 RD Memorial Ayurvedic College, Bhopal (MP), IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 9, No 3 (2017), Pagination: 101-108Abstract
In this systematic review and meta-analysis we compared the efficacy and safety in patient with severe systemic infection (SSF) who has been either on netilmicin (NL) monotherapy or combination of netilmicin with other antibiotics (NLC). A systematic review of the literature was performed in accordance with PRISMA guidelines in Medline and Embase. A comprehensive search was performed from 1978 to 2017. Total 17 studies were identified that include 976 randomized patients with SSF. 489 patients enrolled in 11 studies for NL while 487 in NLC group. The meta-analysis showed that there was a statistically significant difference in rate of clinical efficacy (rate of failure) between NL (13.09%) and comparator NLC (20.91%). Nephrotoxicity associated with the therapy showed minor difference between both group, NL (13.80%) and NLC (10.09%). The study was further compare on the basis of dose regimen viz once a day (OD) and three times a day (TID). 184 patients of 4 studies received once in a day netilmicin monotherapy (OD-NL) while 259 patients of 7 studies received three times a day netilmicin monotherapy (TID-NL).Result of dose regimen group showed 11.04% rate of failure and 11.78% incidence of nephrotoxicity in (OD-NL) and 12.5% and 13.84% respectively in (TID-NL).The paucity of data from this evidence based systematic review and meta-analysis, favors NL monotherapy, if the slightly more chances of nephrotoxicity than comparator NLC neglected.Keywords
Netilmicin, Sever Infection, Netilmicin Combination Therapy, Nephrotoxicity, Meta Analysis.References
- Matthieu L, Adeline M, Benoit S et al. The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care. 2012; 2:1-9.
- Kibe S, Adams K, Barlow G et al. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011; 66:33-40.
- Chesney RW, McCarren DM, Haddad JG, et al. Pathogenic mechanisms of the hypocalcaemia of the staphylococcal toxic shock syndrome. J Lab Clin Med. 1983; 101:576-85.
- Charles VP. Current status of combined antibiotic therapy. J Pediatrics. 1958; 21:1000-09
- Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012; 25:450–70.
- Lubos D, Giampaolo B, Thierry C et al. The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia. Eu J Canc Supp. 2007; 5:13-22
- Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am. 2003; 17:503-28.
- Dana Maglio, Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 2002; 19:341-8.
- Kim Ming Wong, Chan YH, Cheung CY et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis associated peritonitis. Am J Kidney Dis. 2001;38: 127-31
- Endre L et al. Efficacy and safety of ceftriaxone plus netilmicin once daily versus ceftazidime plus netilmicin twice daily in severe nosocomial infections. Cur Therap Research. 1993; 53:687-92.
- Perazella MA. Toxic Nephropathies: Core Curriculum 2010. Am J Kidney Dis. 2010; 55:399-09.
- Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med. 1986; 80:115-8.
- Gonzalez US, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician. 1998; 58:1811-20.
- Richard A, Krieger JN. Gentamicin for the practicing urologist: review of efficacy, single daily dosing and "switch" therapy. J Urology. 2000; 163: 1076-84
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6:1000-10.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986; 7: 177–88.
- Alessandra V Nicolia P, Luca B et al. Comparison of 5 Milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gramnegative pyelonephritis in children, J Antimicrob agents and chemother. 1992; 36: 1499-03
- Auwera P, Meunier F, Ibrahim S et al. Pharmacodynamic parameters and toxicity of netilmicin (6Milligrams/Kilogram/Day) given once daily or in three divided doses to cancer patients with urinary tract infection. J Antimicrob agents and chemother. 1991; 35: 640-7.
- Prat V, Horcicková M, Hatala M et al. Long-term effect of the administration of repeated single doses of netilmicin in urinary tract infections, Cas Lek Cesk. 1990;129:306-8.
- Donald K, Irwin T, James P et al. Pharmacology and efficacy of netilmicin. J Antimicrob agents and chemother. 1978; 13: 832-6.
- Richard DM, Bonnie VB, Paul HE et al. Prospective comparative study of efficacy and toxicity of netilmicin and amikacin. J Antimicrob agents and chemother. 1980; 17:217-25.
- Michael B, Michael WL, Francis PT et al. Prospective randomized trial of netilmicin and amikacin, with emphasis on eighth nerve toxicity. J Antimicrob agents and chemother. 1980; 17:707-14.
- Tange RA, Dreschler WA, Prins JM et al. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol Allied Sci. 1995; 20:118-23.
- Hellum KB, Madsen ST, Digranes A et al. High dose netilmicin therapy of severe or chronic infections. Scand J Infect Dis Suppl. 1980; 23:189-94.
- Perera MR, Amirak ID, Noone P. Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report. Scand J Infect Dis Suppl. 1980; 23:186-8.
- Jahre JA, Fu KP , Neu HC. Clinical evaluation of netilmicin therapy in serious infections. AM J Med 1979; 66:67-73.
- Zhao CA, Li J, Hou J, Guo M et al. Randomized controlled clinical trial on etimicin, a new aminoglycoside antibiotic, versus netilmicin in the treatment of bacterial infections. J Chin Med. 2000; 113:1026-30.
- Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientst. J Antimicrob agents and chemother. 1994; 38: 1309-13.
- CHEK CC, Beryl AP, Heather A et al. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. J Antimicrob agents and chemother. 1989; 33: 87-91.
- Nasu M, Goto Y, Yamasaki T et al. Clinical studies on the time-difference combination therapy with netilmicin and minocycline in methicillin resistant staphylococcus aureus infections Jpn J Antibiot. 1994; 47:1305-17.
- Hoffken G, Pasold R, Pfluger KH et al. An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients J Antimicr Chemo. 1999; 44: 367–76.
- Bubrick MP, Howard RJ , Pancorbo S et al. A comparative study of netilmicin-cefoxitin and gentamicin-cefoxitin in surgical patients with serious systemic infection. Clin Therapeutics. 1983; 5:515-24.
- Kahalley S, Chandler J , Hawkins J et al. Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infections. Clin Therapeutics. 1985; 7:497-06.
- Formulation and Evaluation of Floating Matrix Tablets of Acyclovir using 32 Factorial Design
Abstract Views :244 |
PDF Views:1
Authors
Affiliations
1 SND College of Pharmacy, Babhulgaon, Yeola, Nashik, IN
2 Surgycare Lifescience, Sendhwa, M. P., IN
1 SND College of Pharmacy, Babhulgaon, Yeola, Nashik, IN
2 Surgycare Lifescience, Sendhwa, M. P., IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 10, No 1 (2018), Pagination: 1-9Abstract
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, without affecting the gastric emptying rate. While the system is floating on the gastric contents, the drug is released slowly at a desired rate from the system. These floating tablets mainly prepared for reduction of lag time and release the drug up to 12 hours and may also increase the bioavailability of the drugs by utilizing the drug to full extent avoiding unnecessary frequency of dosing. The study included formulation of floating tablets using polymers like Hydroxy propyl methyl cellulose K15M, PVP K30, Sodium bicarbonate, Xanthan-Gum, Guar-gum and microcrystalline cellulose as matrix forming agents. The tablets were directly compressed using Lab Press multi station rotary punching machine. FTIR and DSC-TGA studies conformed that there was no incompatibility between the polymers and the drug. Tablet preformulation parameters were within the Pharmacopoeias limit. Tablet showed zero lag time, continuance of buoyancy for >12 h. In vivo X-ray studies depicted that tablets continued to float in the GIT for 12 h. The in-vitro drug release pattern of Acyclovir floating tablets was fitted to different kinetic models which showed highest regression for zero order kinetics with Koresmeyer-peppasand most of the formulations followed Nonfickian diffusion.Keywords
Acyclovi, Floating Drug Delivery System, HPMC, PVP K30, Xanthan-Gum, Guar-Gum, Matrix Devices, Gastroretentive Dosage Forms.References
- Moffat, A. C, Osselton, M. D, Widdop, B. Clarke’s Analysis of Drugs and Poisons. Pharma ceutical Press, London, 2004 2(3), 582.
- Sweetman, S. C. Martindale. Pharmaceutical Press, London, 2005, (34), 626.
- Gisbold‟ s Willson. Text Book of Organic Medicinal and Pharmaceutical Chemistry, Lippincott Williams and Wilkins, New York. London. 2004, (11) 372.
- Tripathi KD, Essential of Medical Pharmacology, Jaypee Brothers, Medical, Publisher, (P) LTD, New Delhi. 2008, (6) 767.
- Mridanga R.R, Bose S.K. and Sengupta K. Design, Development and in vitro evolution of directly compressed sustained release matrix tablet of famotidine. Research J. Pharm and Tech., 2008, 1(3): 175-178.
- Ajay B, Dinesh KP, Pradeep S. Studies on formulation and evaluation of floating tablets ofciprofloxacin. Int J Compren Pharma. 2010; 5(2): 1-3.
- Rocca JG, Omidian H, Shah K. Progress in Gastro retentive drug delivery system, Drug Delivery Oral. Pharm.Tech. 2003; 152–156.
- M, Zia H, Rhodes T. Design and testing in vitro of a bioadhesive and floatingdrugdelivery system for oral application. Int J Pharm. 1994; 105(1): 65-70.
- Sheth PR, Tossounian J. The hydrodynamically balanced system (HBS): a novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 1994; 20: 313–339.
- Krunal PM, Biswajit B, Nabin K, Janki P. Preparation and evaluation of gastro retentivefloating tablets of mebendazole. Int J Curr Pharma Res. 2011; 3(1): 63-65.
- Sheth PR, Tossounian J. The hydrodynamically balanced system (HBS): a novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 1994; 20: 313–339.
- Jadhav MN, Shanmugam S, Sundaramoorthy K, Ayyappan T, Vetrichelvan T.Formulation and in-vitro evaluation of gastro retentive floating matrix tablets of famotidine. Int J Pharma and Bio Sci, 2010; 4(1): 548-58.
- Friend DR. Oral delivery: A new approach to dosage forms. Pharmaceutical News 2002; 9: 375-80.
- Chein YW. Oral Drug Delivery and Delivery systems. In, Novel drug delivery Systems, Marcel Dekker, Inc, New York, 1992, 50(4), 139-177.
- Kavitha K, Puneeth KP, Tamizh MT. Development and evaluation of rosiglitazone maleatefloating tablets using natural gums. IJPT Res. 2010; 2(3): 1662-66.
- Orazio Luca Strusi, Gaia Colombo, Pedro Barata, Paolo Colombo. Module assemblage technology for floating systems: In vitro flotation and in vivo gastro-retention. J Control release; 2008, 129(3), 188-192.
- Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR., Development and invitro evaluation of an oral floating matrix tablet formulation of Diltiazem hydrochloride, AAPS Pharm Sci Tech, 2007; 8(3): E 73.
- Patel SS, Ray S, Thakur RS., Formulation and evaluation of floating drug delivery system containing Clarithromycin for Helicobacter pylori, Acta Pol Pharm, 2006; 63(1): 53-61.
- Jaimini M, Rana AC, Tanwar YS., Formulation and evaluation of Famotidine floating tablets, Curr Drug Deliv. 2007; 4(1): 51-5.
- Thahera PD, Ashok, Latha K, Shailaja T, Nyamathulla S, UhumwanghoMU,Formulation and evaluation of Norfloxacin gastroretentive drug delivery systems using natural polymers, International current pharmaceutical journal, 2012; 1(7): 155-164.
- Patel Ishvar C, Hariprasnna RC, Mohan V Kodli, Patel vishal A, Pentewar Ram P,Formulation and evaluation of floating matrix tablets of Ketorolac tromethamine, IJPI’S Journal of pharmaceutics and Cosmetology, 2011; 2: 7.
- Gohel MC, Mehta PR, Dave PK, Bariya NH. More relevant dissolution method for evaluation of PDDS. Dissolution technol, 2005; 11: 22‐5.
- Swarna Kamala Chinthala CH, Srinivas Reddy Kota K, Hadassah M, HepsibhaMetilda E,Sridevi S, Fomulation and evaluation of gastroretentive floating tablets of Gabapentin using Effervescent technology, Int J Pharm Biomed Res 2012; 3(4): 202-208.
- Patel Sanjay S, Ray S. and Thakur R. S. Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter Pylori. Acta Pol Pharma Dr Res, 2006, 63(1) 53-61.
- B, Dinesh KP, Pradeep S. Studies on formulation and evaluation of floating tablets ofciprofloxacin. Int J Compren Pharma. 2010; 5(2): 1-3.